TABLE 5.
Summary of dasatinib and crizotinib pharmacokinetic parameters
| Drug | Dose (mg/m2) | Day of therapy | Number of. patients | Cmax (ng/mL) | AUC0→t (ng/mL/hr) |
|---|---|---|---|---|---|
| Dasatinib | 50 | 14 | 10 | 119.8 (54.1 to 385.8) | 593.8 (388.1 to 1,521.1) |
| 65 | 14 | 2 | 209.5 (95.7 to 323.2) | 863.9 (721.9 to 1,006) | |
| Crizotinib | 100 | 1 | 3 | 49.1 (42 to 97.8) | 1,288.9 |
| 100 | 14 | 3 | 392.6 (383 to 487.4) | 5,706 (4,740.9 to 6,671.9) | |
| 130 | 1 | 5 | 95.7 (57.5 to 155.5) | 2,189.4 (1,261.5 to 2,668.5) | |
| 130 | 14 | 5 | 443.9 (254.4 to 793.7) | 5,486.1 (4,286.6 to 10,869) | |
| 165 | 1 | 9 | 155.5 (55.8 to 324.4) | 3,360.1 (1,457.5 to 4,939.1) | |
| 165 | 14 | 7 | 155.9 (95.9 to 343.1) | 1,933.8 (1,678.1 to 6,210.4) | |
| 215 | 1 | 8 | 278.8 (123.1 to 690.2) | 5,326.3 (2,068.3 to 12,182.9) | |
| 215 | 14 | 4 | 261.9 (93.8 to 356.2) | 3,118.9 (1,693.8 to 4,278.5) |
Of note, results are shown as median (ranges in parentheses)
AUC0→t of crizotinib were t= ∞ for day 1 and t= 24 hours for day 14